CohBar, Inc. (CWBR): Price and Financial Metrics


CohBar, Inc. (CWBR)

Today's Latest Price: $1.01 USD

0.10 (10.42%)

Updated Sep 25 4:00pm

Add CWBR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

CWBR Daily Price Range
CWBR 52-Week Price Range

CWBR Stock Price Chart Technical Analysis Charts


CWBR Price/Volume Stats

Current price $1.01 52-week high $4.25
Prev. close $0.91 52-week low $0.85
Day low $0.97 Volume 1,097,615
Day high $1.05 Avg. volume 305,092
50-day MA $1.32 Dividend yield N/A
200-day MA $1.82 Market Cap 46.12M

CohBar, Inc. (CWBR) Company Bio


CohBar, Inc., a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus. The company is also developing Humanin, a mitochondrial-derived peptide to treat Alzheimer's disease, atherosclerosis, myocardial and cerebral ischemia, and type 2 diabetes mellitus; SHLP-6 for the treatment of cancer; and SHLP-2 to treat Alzheimer's disease and type 2 diabetes mellitus. CohBar, Inc. was founded in 2007 and is headquartered in Menlo Park, California.


CWBR Latest News Stream


Event/Time News Detail
Loading, please wait...

CWBR Latest Social Stream


Loading social stream, please wait...

View Full CWBR Social Stream

Latest CWBR News From Around the Web

Below are the latest news stories about CohBar Inc that investors may wish to consider to help them evaluate CWBR as an investment opportunity.

CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit

MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit, being held virtually on September 21-23, 2020. Oppenheimer Fall Healthcare, Life Sciences, & Med Tech Summit Tuesday, September 22 at 2:30 PM ET Webcast: The presentation may be accessed via webcast at the scheduled time, or following the presentation, using the following link: https://wsw.com/webcast/oppenheimer5/cwbr/2713518.About CohBarCohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focu...

Yahoo | September 10, 2020

CohBar Announces Closing of Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the closing of its previously announced underwritten public offering of 12,300,000 units at a price to the public of $1.22 per unit.  Each unit consists of one share of the Company’s common stock and one warrant to purchase 0.75 of a share of common stock at a per share exercise price of $1.44. In addition, the underwriters partially exercised the over-allotment option for warrants to purchase an additional 1,383,750 shares. The warrants are exercisable for five years from the closing date of the offering. The aggregate gross proceeds from...

Yahoo | August 28, 2020

CohBar plunges in early trade post pricing underwritten public offering

CohBar (CWBR) plunged in trade post it priced earlier announced underwritten public offering of 12.3M units at $1.22/unit; each unit consists of one share and one warrant to purchase 0.75 of a share at a per share exercise price of $1.44.Warrants have a 5-year expiry from offer close date which...

Seeking Alpha | August 26, 2020

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the pricing of an underwritten public offering of 12,300,000 units at a price to the public of $1.22 per unit.  Each unit consists of one share of the Company’s common stock and one warrant to purchase 0.75 of a share of common stock at a per share exercise price of $1.44. Each warrant will be exercisable for five years from the closing date of the offering. The aggregate gross proceeds from this offering are expected to be approximately $15.0 million, before deducting underwriting discounts and commissions and estimated offering expenses ...

Yahoo | August 26, 2020

CohBar readies stock public offering

CohBar (CWBR) announces a proposed underwritten public offering of units consisting of one common share and one warrant to purchase 0.75 of a share within 5 years. Price, terms and volume not yet disclosed.Underwriters' overallotment option is additional 15% of units offered.CohBar intends to use the net proceeds for general corporate purposes, including...

Seeking Alpha | August 25, 2020

Read More 'CWBR' Stories Here

CWBR Price Returns

1-mo 16.47%
3-mo -45.70%
6-mo -15.83%
1-year -22.90%
3-year -63.27%
5-year -14.12%
YTD -36.88%
2019 -48.55%
2018 -37.42%
2017 142.44%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7429 seconds.